Ness Bermingham looks to lead the wave of RNA editing at new Atlas upstart Korro Bio
By the time Ness Bermingham left Intellia in late 2017, the gene-editing biotech had secured its footing as one of the pioneers in the CRISPR/Cas9 space with a highly anticipated first-in-human trial in the works. Returning to his VC post at Atlas Venture, he signaled that he was looking to do it all over again with the next big startup idea.
And now he’s ready to talk about that venture, which represents the latest evolution of his longstanding interest in tinkering with the genome — RNA editing.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 76,800+ biopharma pros reading Endpoints daily — and it's free.